Advanced search
Publication Cover
Cancer Investigation Volume 12, 1994 - Issue 3
Submit an article Journal homepage
35
Views
20
CrossRef citations to date
0
Altmetric
Original Article

A Feasibility Study of Extended Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B

Gerald Clamon Department of Internal Medicine, University of Iowa College of Medicine
,
James Herndon CALGB Statistical Center, Duke University Medical Center
,
Walter Eaton Department of Radiation Therapy, Dartmouth College School of Medicine
,
Julian Rosenman Department of Radiation, Oncology University of North Carolina School of Medicine
,
L. Herbert Maurer Department of Internal Medicine, Dartmouth College School of Medicine
,
M. Robert Cooper Department of Internal Medicine, Bowman Gray School of Medicine
&
Mark R. Green Department of Internal Medicine, University of California San Diego School of Medicine
 show all
Pages 273-282 | Published online: 11 Jun 2009

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Everett E. Vokes & Mark R. Green. (1998) Clinical Studies in Non-small Cell Lung Cancer: The CALGB Experience. Cancer Investigation 16:2, pages 72-79.
Read now
Martin H. Cohen. (1994) A Path Through the Forest. Cancer Investigation 12:3, pages 360-361.
Read now

Articles from other publishers (18)

Y. Lievens, P. Giraud, C. Faivre-Finn, P. Gustin & C. Le Pechoux. (2021) Cancers bronchiques de stade III : rôle de l’onco-radiothérapeute. Revue des Maladies Respiratoires Actualités 13:2, pages 2S97-2S108.
Crossref
Ronald J. Maggiore, David Zahrieh, Ryan P. McMurray, Josephine L. Feliciano, Pamela Samson, Pranshu Mohindra, Hongbin Chen, Melisa L. Wong, Jacqueline M. Lafky, Aminah Jatoi & Jennifer G. Le-Rademacher. (2021) Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812). Journal of Geriatric Oncology 12:4, pages 563-571.
Crossref
P. Giraud, C. Faivre-Finn, P. Gustin & C. Le Pechoux. (2019) Cancers bronchiques de stade III: rôle de l’onco-radiothérapeute. Revue des Maladies Respiratoires Actualités 11:3, pages 278-289.
Crossref
Jing Zhao, Yingfeng Xia, Joseph Kaminski, Zhonglin Hao, Frank Mott, Jeff Campbell, Ramses Sadek & Feng-Ming (Spring) Kong. (2016) Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLOS ONE 11:6, pages e0157455.
Crossref
Xiu‑Jun Chang, Zi‑Tong Wang & Lei Yang. (2016) Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis. Molecular and Clinical Oncology.
Crossref
S.E. Schild & E.E. Vokes. (2016) Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Annals of Oncology 27:4, pages 590-599.
Crossref
Rudolf M. Huber, Martin Reck & Michael Thomas. (2013) Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. European Respiratory Journal 42:4, pages 1119-1133.
Crossref
Anne AupérinCecile Le PéchouxEstelle RollandWalter J. CurranKiyoyuki FurusePierre FournelJose BelderbosGerald ClamonHakki Cuneyt UlutinRebecca PaulusTakeharu YamanakaMarie-Cecile BozonnatApollonia UitterhoeveXiaofei WangLesley StewartRodrigo ArriagadaSarah BurdettJean-Pierre Pignon. (2010) Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 28:13, pages 2181-2190.
Crossref
C. C. E. Koning, J. S. A. Belderbos & A. L. J. Uitterhoeve. (2010) From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions. Chemotherapy Research and Practice 2010, pages 1-5.
Crossref
Nicolas Girard & Françoise Mornex. (2009) Radiotherapy for locally advanced non-small cell lung cancer. European Journal of Cancer 45, pages 113-125.
Crossref
James E. HerndonIIII, Alice B. Kornblith, Jimmie C. Holland & Electra D. Paskett. (2008) Patient Education Level As a Predictor of Survival In Lung Cancer Clinical Trials. Journal of Clinical Oncology 26:25, pages 4116-4123.
Crossref
Gordon Okawara, Jean A. Mackay, William K. Evans & Yee C. Ung. (2006) Management of Unresected Stage III Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology 1:4, pages 377-393.
Crossref
Mark A. Socinski. (2005) Combined Modality Trials in Unresectable Stage III Non-Small Cell Lung Cancer: The Cancer and Leukemia Group B Experience. Seminars in Oncology 32, pages 114-118.
Crossref
M.A. Socinski, C. Zhang, J.E. HerndonIIII, R.O. Dillman, G. Clamon, E. Vokes, W. Akerley, J. Crawford, M.C. Perry, S.L. Seagren & M.R. Green. (2004) Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Annals of Oncology 15:7, pages 1033-1041.
Crossref
Stephen L Graziano, Arthur Tatum, James E HerndonIIII, James Box, Vincent Memoli, Mark R Green & Jeffrey A Kern. (2001) Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33:2-3, pages 115-123.
Crossref
Jacek Jassem. (2001) Combined chemotherapy and radiation in locally advanced nonsmall-cell lung cancer. The Lancet Oncology 2:6, pages 335-342.
Crossref
Gerald ClamonJames HerndonRobert CooperAlex Y. ChangJulian RosenmanMark R. Green. (1999) Radiosensitization With Carboplatin for Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: A Phase III Trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 17:1, pages 4-4.
Crossref
M.R. Green & R.C. Lilenbaum. (1995) Issues at the cutting edge in stage III non-small-cell lung cancer. Annals of Oncology 6, pages S33-S36.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.